Amphotericin B-Loaded Emulgel: Effect of Chemical Enhancers on the Release Profile and Antileishmanial Activity In Vitro

Cutaneous leishmaniasis is a neglected parasitic disease. Treatment is preferably performed with pentavalent antimony associated or not with amphotericin B (AmB). This study aimed to develop an emulgel with different chemical enhancers of cutaneous release. Initially, AmB emulsions were obtained with the chemical promoters, oleic acid and geraniol and without promoter, then for the evaluation of the formulations, a preliminary stability study was carried out where the formulations were submitted to centrifugation, before and after the freeze-thaw cycle and analyzed appearance, color, pH, spreadability, viscosity, conductivity, droplet size, assay, in vitro release study, in vitro antileishmania activity in Leishmania major promastigotes, and macrophage toxicity in the MTT test. The emulsions were yellowish, with no signs of instability after the centrifugation test. The pH range corresponded to that of the skin, which is 4.6 to 5.8, before and after the freeze-thaw cycle, the formulations had good spreadability and did not present significant viscosity differences before and after the freeze-thaw cycle, presenting a non-Newtonian characteristic. AmB content was within the kinetic model of zero order release, the formulation of 3% AmB and 5% oleic acid (formulation 1) was chosen to proceed with the antileishmania activity test and showed potential activity against the in vitro parasite with significant reduction of cytotoxicity on murine macrophages, indicating that the formulation is promising for the treatment of cutaneous leishmaniasis.

[1]  I. M. Pinheiro,et al.  Emulgel based on amphotericin B and bacuri butter (Platonia insignis Mart.) for the treatment of cutaneous leishmaniasis: characterization and in vitro assays , 2018, Drug development and industrial pharmacy.

[2]  Yunmei Song,et al.  Evaluation of Transdermal Drug Permeation as Modulated by Lipoderm and Pluronic Lecithin Organogel. , 2018, Journal of pharmaceutical sciences.

[3]  C. Limmatvapirat,et al.  Formulation and evaluation of gels containing coconut kernel extract for topical application , 2018, Asian journal of pharmaceutical sciences.

[4]  Yu-Hsiang Lin,et al.  Microemulsion formulation design and evaluation for hydrophobic compound: Catechin topical application. , 2018, Colloids and surfaces. B, Biointerfaces.

[5]  D. Santos,et al.  In Vitro Immunomodulatory Activity of a Transition-State Analog Inhibitor of Human Purine Nucleoside Phosphorylase in Cutaneous Leishmaniasis , 2017, Journal of immunology research.

[6]  M. Chaves,et al.  Gallic and ellagic acids: two natural immunomodulator compounds solve infection of macrophages by Leishmania major , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  D. Arcanjo,et al.  In Vitro Effects of the Neolignan 2,3‐Dihydrobenzofuran Against Leishmania Amazonensis , 2017, Basic & clinical pharmacology & toxicology.

[8]  D. Menezes-Souza,et al.  Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis. , 2016, Experimental parasitology.

[9]  I. M. Pinheiro,et al.  Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis. , 2016, Experimental parasitology.

[10]  M. Morilla,et al.  Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro. , 2016, Colloids and surfaces. B, Biointerfaces.

[11]  Preeti K. Suresh,et al.  Development and In Vitro Characterization of Piroxicam Loaded Emulgel for Topical Delivery , 2015 .

[12]  M. Lane,et al.  Formulation of diclofenac for dermal delivery. , 2014, International journal of pharmaceutics.

[13]  D. Gowda,et al.  Calcipotriol delivery into the skin as emulgel for effective permeation , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[14]  Ghada E. Yassin Formulation and Evaluation of Optimized Clotrimazole Emulgel Formulations. , 2014 .

[15]  R. Asija,et al.  EMULGEL: A NOVEL APPROACH TO TOPICAL DRUG DELIVERY , 2013 .

[16]  Ajazuddin,et al.  Recent expansions in an emergent novel drug delivery technology: Emulgel. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[17]  E. V. Faria,et al.  Quantitative descriptive analysis of probiotic buttermilk/Analise descritiva quantitativa de buttermilk probiotico , 2012 .

[18]  S. Gurpreet,et al.  Development and Characterization of Clarithromycin Emulgel for topical delivery , 2012 .

[19]  M. Santoro,et al.  Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species. , 2011, Parasitology international.

[20]  Ranieri Campos,et al.  ASPECTOS TEÓRICOS RELACIONADOS À REOLOGIA FARMACÊUTICA , 2010 .

[21]  S. Mitragotri,et al.  Enhancement of transdermal drug delivery via synergistic action of chemicals. , 2009, Biochimica et biophysica acta.

[22]  S. R. Machado,et al.  Emulsões O/A contendo Cetoconazol 2,0%: avaliação da estabilidade acelerada e estudos de liberação in vitro , 2009 .

[23]  P. J. Neto,et al.  Modelos de Avaliação da Estabilidade de Fármacos e Medicamentos para a Indústria Farmacêutica , 2009 .

[24]  G. Yener,et al.  Effect of Vehicles on Release of Meloxicam from Various Topical Formulations , 2009 .

[25]  A. Foroumadi,et al.  Leishmanicidal Evaluation of Novel Synthetic Chromenes , 2008, Archiv der Pharmazie.

[26]  Gisele Mara Silva Gonçalves,et al.  Aplicação de métodos de biofísica no estudo da eficácia de produtos dermocosméticos , 2009 .

[27]  A. Foroumadi,et al.  Leishmanicidal Evaluation of Novel Synthetic Chromenes , 2008, Archiv der Pharmazie.

[28]  S. Mazzitelli,et al.  Rheological and functional characterization of new antiinflammatory delivery systems designed for buccal administration. , 2008, International journal of pharmaceutics.

[29]  M. Parnianpour,et al.  In-vitro release of diclofenac diethylammonium from lipid-based formulations. , 2002, International journal of pharmaceutics.

[30]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  M. T. Knorst Desenvolvimento tecnológico de forma farmacêutica plástica contendo extrato concentrado de Achyrocline satureioides (Lam.) DC. Compositae (marcela) , 1991 .